Ascendiant Capital Markets Issues Positive Forecast for Allarity Therapeutics (NASDAQ:ALLR) Stock Price

Posted by Joseph Casey on Sep 16th, 2026

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) had its price objective lifted by equities research analysts at Ascendiant Capital Markets from $10.25 to $11.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other analysts have also issued reports on ALLR. Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $11.00.

Check Out Our Latest Analysis on Allarity Therapeutics

Allarity Therapeutics Trading Down 5.1%

Shares of ALLR stock opened at $1.11 on Wednesday. The company has a market capitalization of $17.66 million, a price-to-earnings ratio of -1.42 and a beta of 0.56. The firm has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.32. Allarity Therapeutics has a twelve month low of $0.77 and a twelve month high of $1.84.

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.04. As a group, research analysts predict that Allarity Therapeutics will post -0.92 earnings per share for the current year.

Allarity Therapeutics Company Profile

(Get Free Report)

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.